A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

• ClinicalTrials.gov Identifier: NCT03789604
• Recruitment Status: Active, not recruiting
• First Posted: December 28, 2018
• Last Update Posted: November 9, 2022
• Sponsor: CStone Pharmaceuticals
• Information provided by (Responsible Party): CStone Pharmaceuticals

Study Description

Brief Summary:

This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC).

Condition or disease	Intervention/treatment	Phase
Non Small Cell Lung Cancer	Biological: CS1001 monoclonal antibody; Biological: CS1001 placebo	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 479 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Multi-Center, Randomized, Double-Blind, Phase III Study of Platinum-Containing Chemotherapy With or Without CS1001 in Stage IV Non-Small Cell Lung Cancer Subjects
• Actual Study Start Date: December 13, 2018
• Actual Primary Completion Date: June 8, 2020
• Estimated Study Completion Date: August 31, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: CS1001 monoclonal antibody	Biological: CS1001 monoclonal antibody; Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
Placebo Comparator: CS1001 placebo	Biological: CS1001 placebo; Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle

Outcome Measures

Primary Outcome Measures :

1. Progression-free survival (PFS) in all subjects evaluated by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, up to approximately 30 months ]

Secondary Outcome Measures :

1. Overall Survival (OS) [ Time Frame: Randomization date to all-cause death date (up to approximately 30 months) ]
   OS defined as the time from randomization to all-cause death.
2. PFS assessed by BICR [ Time Frame: Randomization until the first occurrence of disease progression or all-cause death, whichever occurs first (up to approximately 30 months) ]
   PFS defined as the time from randomization to the first occurrence of disease progression or all-cause death (whichever occurs first), as determined by the BICR according to RECIST v1.1
3. PFS in subgroup of participants with PD-L1 Expression≥1%, as determined by the investigator [ Time Frame: Randomization until the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 30 months) ]
   PFS after randomization as determined by the investigator according to RECIST v1.1 in the subgroup of patients with PD-L1 expression ≥1% defined by the SP263 immunohistochemistry (IHC) assay.
4. Objective Response Rate (ORR) assessed by the investigator according to RECIST v1.1 [ Time Frame: Randomization until disease progression or death, whichever occurs first (up to approximately 30 months) ]
   ORR, defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions >=4 weeks apart, as determined by the investigator according to RECIST v1.1.
5. Duration of response (DOR) assessed by the investigator according to RECIST v1.1 [ Time Frame: the time between the date of the earliest qualifying response and the date of progressive disease or all-cause death, whichever occurs first (up to approximately 30 months) ]
   DOR defined as the time between the date of the earliest qualifying response and the date of progressive disease or all-cause death, whichever occurs first, as determined by the investigator according to RECIST v1.1.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Willing to participate in this trial; fully understand and informed of this trial, and able to provide written informed consent form (ICF).
2. 18-75 years of age (18 and 75 included) on the day of signing ICF.
3. Histologically or cytologically confirmed stage IV non-small cell lung cancer (staged according to the 8th International Association for the Study of Lung Cancer (IASLC) classification.
4. Subjects haven't received systemic treatment for advanced/metastatic NSCLC.
5. Measurable target lesion evaluated by investigators according to RECIST v1.1.
6. ECOG PS of 0-1.
7. Life expectancy ≥ 12 weeks.
8. Subject with prior anti-cancer treatment can only be enrolled when all toxicities except for hearing loss, alopecia and fatigue, of prior anti-cancer treatment has recovered to ≤ Grade 1 according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
9. Subjects must have adequate organ function.
10. Women of childbearing potential (WOBPC, as defined in section 13.5) must have a negative pregnancy test ≤7 days prior to the first dose of investigational product. WOBCP or fertile men and their WOBCP partners must agree to use an effective method of birth control from providing signed ICF and for 6 months after last dose of investigational product.

Exclusion Criteria:

1. Histologically confirmed small cell lung cancer or containing small cell component.
2. Subjects with current active autoimmune disease or prior history of autoimmune disease.
3. Malignancies other than NSCLC within 5 years prior to randomization.
4. Known history of human immunodefiency virus (HIV) infection and/or acquired immune deficiency syndrome.
5. Subject with active hepatitis B or hepatitis C.
6. Subjects with known history of alcoholism or drugs abuse.
7. Has a known hypersensitivity to any component of study treatment, for example pemetrexed, cisplatin, carboplatin or other platinum compounds.
8. Subjects with other conditions that in the investigator's opinion may influence subject's compliance or make subjects not suitable for participating in this trial.

Contacts and Locations

Locations

China, Shanghai

Shanghai Pulmonary Hospital

Shanghai, Shanghai, China

Sponsors and Collaborators

CStone Pharmaceuticals

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14.

• Responsible Party: CStone Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT03789604
• Other Study ID Numbers: CS1001-302
• First Posted: December 28, 2018
• Last Update Posted: November 9, 2022
• Last Verified: November 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Antibodies; Antibodies, Monoclonal; Immunologic Factors; Physiological Effects of Drugs